Korro Bio, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Korro Bio, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.39M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.27M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 18, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 10, 2023 |
| FY2022 | Dec 31, 2021 | $14.07M | Mar 10, 2023 |
| FY2020 | Dec 31, 2020 | $9.95M | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | $11.25M | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | $8.52M | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | $7.26M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $4.71M | Mar 29, 2021 |
| FY2020 | Sep 30, 2019 | $24.24M | Mar 29, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($117.26M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($83.58M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($81.17M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($58.03M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($84.69M) | Mar 10, 2023 |
| FY2020 | Dec 31, 2020 | ($10.23M) | Mar 29, 2021 |
| FY2020 | Sep 30, 2020 | ($5.34M) | Mar 29, 2021 |
| FY2020 | Jun 30, 2020 | ($6.03M) | Mar 29, 2021 |
| FY2020 | Mar 31, 2020 | ($4.91M) | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | ($5.49M) | Mar 29, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($121.86M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($91.91M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($84.53M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($59.00M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($84.03M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($27.55M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($20.68M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($18.94M) | Mar 26, 2020 |
| FY2019 | Dec 31, 2017 | ($16.31M) | Mar 26, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.58M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $63.64M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $57.25M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $42.20M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $60.92M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $37.42M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $18.78M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $11.88M | Mar 26, 2020 |
| FY2019 | Dec 31, 2017 | $11.97M | Mar 26, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($78.56M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($60.07M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($67.28M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($53.65M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($76.06M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($45.19M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $34.22M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($17.02M) | Mar 26, 2020 |
| FY2019 | Dec 31, 2017 | ($14.61M) | Mar 26, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $518.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $17.90M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $7.84M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $5.14M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $2.91M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $6.67M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.06M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $436.0K | Mar 26, 2020 |
| FY2019 | Dec 31, 2017 | $1.86M | Mar 26, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.51M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $226.24M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $221.66M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $73.74M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $185.36M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $264.72M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $223.22M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $44.55M | Mar 26, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.07M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $65.83M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $51.75M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $8.91M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $54.53M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $72.23M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $55.86M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $4.12M | Mar 26, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($383.85M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($266.59M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($183.01M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($101.83M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($180.09M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($95.40M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($68.89M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($49.09M) | Mar 26, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.82M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $55.64M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $166.15M | Mar 18, 2025 |
| FY2024 | Nov 3, 2023 | $36.60M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $36.33M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $79.64M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $220.34M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $200.16M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $42.19M | Mar 26, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (12) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (53) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (227) | Mar 26, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (12) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (53) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (227) | Mar 26, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.42M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 9.38M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 8.02M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 268,468 | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 34.61M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 33.96M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 30.84M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 2.08M | Mar 26, 2020 |